Direct-To-Patient Programs Unveiled As MFN Pricing Deadline Looms

 
• By Alaric DeArment
  
Bristol Myers Squibb and AstraZeneca announced new direct-to-patient sales programs. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip